An interventional study of MRI ZTE2 sequence in Spondyloarthropathy and Tendinopathy, sponsored by University Hospital, Bordeaux. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Diagnostic
The purpose of this study is to accurately map calcaneal fibrocartilage using TE = 0 ms imaging, and then apply measurements of our control population to SpA patients with peripheral enthesis study using the calcaneal tendon as a clinical model
The human body contains a lot of tissue components with short T2 (transversal relaxation time) that are not or only poorly detected on conventional T2-weighted MR sequences. These components are mostly located in musculoskeletal organs such as tendons, ligaments, menisci, periosteum or cortical bone.
Considering that conventional sequences do not detect tissue components with T2 shorter than 10ms, imaging of body tendon or enthesis is therefore very limited. This represents a limitation of MR imaging in early diagnosis of a certain number of pathologies, such as mechanical or mostly inflammatory tendinopathy or enthesopathy.
This study, would provide the feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy Achilles tendon enthesis at 3 T, and would demonstrate that this sequence allows the detection of SpA enthesopathy prior to conventional sequences and enables disease monitoring.
For those purposes, during inclusion visit sequences ZTE 2 and UTE (with and without gadolinium injection) will be add to routine macrocyclic gadolinium injected MRI of 3 groups of patients (symptomatic and non sympatomatic spondyloarthropathy and mechanical tendinopathy). Healthy volunteer group will undergo an MRI exam without gadolinium injection comprised of following sequences T2 FS, T1, DP FS, ZTE 2 and UTE.
No follow up visit are schedule in this study
Additional criteria for each group:
GROUP 1: HEALTHY VOLUNTEERS
GROUP 2: SPA + NON-SYMPTOMATICS AT THE CALCANEEN FIBROCARTILAGE LEVEL
GROUP 3: SPA + SYMPTOMATICS AT THE CALCANEEN FIBROCARTILAGE LEVEL
GROUP 4: MECHANIC TENDINOPATHY
Exclusion Criteria:
Additional criteria for GROUPS 2, 3 and 4:
* 3D sequence ZTE2 DP without gadolinium * 3D Sequence UTE without gadolinium
Device: MRI ZTE2 sequence
* 3D sequence ZTE2 DP without gadolinium * 3D Sequence UTE without gadolinium * 3D Sequence ZTE2 DP with gadolinium * 3D sequence UTE with gadolinium
Device: MRI ZTE2 sequence
* 3D sequence ZTE2 DP without gadolinium * 3D Sequence UTE without gadolinium * 3D Sequence ZTE2 DP with gadolinium * 3D sequence UTE with gadolinium
Device: MRI ZTE2 sequence
* 3D sequence ZTE2 DP without gadolinium * 3D Sequence UTE without gadolinium * 3D Sequence ZTE2 DP with gadolinium * 3D sequence UTE with gadolinium
Device: MRI ZTE2 sequence
feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
Maximum ZTE signal value in healthy volunteers
Time frame: baseline
Maximum difference of the ZTE signal value between healthy volunteers and non-symptomatic SpA + patients in the calcaneal fibrocartilage
Time frame: baseline
Maximum difference of the ZTE signal value between healthy volunteers and symptomatic SpA + patients in the calcaneal fibrocartilage
Time frame: baseline
Maximum difference in the ZTE signal value between healthy volunteers and patients with mechanical tendinopathy
Time frame: baseline
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux